secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001140361-25-007867
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore HIV cure candidate IMC-M113V shows dose-dependent viral control in Phase 1/2 MAD data at CROI 2025
--------------------------------------------------------------------------------

- Well tolerated across 60-300 mcg doses; no dose-limiting toxicities or serious AEs; mild CRS in 5 of 6 at 300 mcg.
- 3 of 15 evaluable PLWH showed delayed viral rebound or viremia control after ART interruption; 2 remained off ART for full 12 weeks.
- Dose-dependent reduction in active reservoir (CD4+ Gag RNA) and trend of intact HIV DNA reduction at higher doses.
- Enrollment continues with higher doses; expansion cohorts planned at one or more doses.
- IMC-M113V is first TCR bispecific targeting HIV in clinic, aims for functional cure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125007867/0001140361-25-007867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125007867/ef20045169_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-007867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer